What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

Similar documents
What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Tuberculosis Update. Topics to be Addressed

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Diagnosis and Medical Management of Latent TB Infection

TB Update: March 2012

Tuberculosis Tools: A Clinical Update

Tuberculosis Intensive

Contracts Carla Chee, MHS May 8, 2012

10/3/2017. Updates in Tuberculosis. Global Tuberculosis, WHO 2015 report. Objectives. Disclosures. I have nothing to disclose

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB Prevention Who and How to Screen

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

TUBERCULOSIS. Pathogenesis and Transmission

Diagnosis & Medical Case Management of TB Disease. Lisa Armitige, MD, PhD October 22, 2015

Advanced Management of Patients with Tuberculosis Little Rock, Arkansas August 13 14, 2014

Diagnosis Latent Tuberculosis. Disclosures. Case

Making the Diagnosis of Tuberculosis

Approaches to LTBI Diagnosis

TB Nurse Case Management San Antonio, Texas March 7 9, Pediatric TB Kim Connelly Smith, MD, MPH March 8, 2012

Interpretation of TST & IGRA results. Objectives

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

TB is Global. Latent TB Infection (LTBI) Sharing the Care: Working Together. September 24, 2014

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

has the following disclosures to make:

TB Intensive Houston, Texas. Childhood Tuberculosis Kim Connelly Smith. November 12, 2009

LTBI: Who to Test & When to Treat

TB Intensive Tyler, Texas December 2-4, 2008

Peggy Leslie-Smith, RN

Latent TB, TB and the Role of the Health Department

TB in Corrections Phoenix, Arizona

INDEX CASE INFORMATION

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Disclosures. Updates in TB for the PCP: Opportunities for Prevention. Objectives PART 1: WHY TEST? 4/14/2016. None

Conflict of Interest Disclosures:

Pediatric TB Lisa Armitige, MD, PhD September 28, 2011

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Pediatric Tuberculosis Lisa Y. Armitige, MD, PhD September 14, 2017

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

Latent TB Infection (LTBI)

TB Intensive Houston, Texas October 15-17, 2013

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

Diagnosis and Medical Management of LTBI

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

TB Intensive San Antonio, Texas August 7-10, 2012

TB Intensive San Antonio, Texas November 11 14, 2014

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Fundamentals of Tuberculosis (TB)

11/1/2017. Disclosures. Update In Tuberculosis, Indiana Outline/Objectives. Pathogenesis of M.tb Global/U.S. TB Burden, 2016

Diagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Self-Study Modules on Tuberculosis

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

TB Contact Investigation

Latent TB Infection (LTBI) Strategies for Detection and Management

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

Diagnosis of Tuberculosis Infection and Disease

Diagnosis of tuberculosis

TB Nurse Case Management San Antonio, Texas March 7 9, Clinical Diagnosis and

New Approaches to the Diagnosis and Management of Tuberculosis Infection in Children and Adolescents

TB Intensive San Antonio, Texas

TB Classification (ATS/CDC)

Management of Pediatric Tuberculosis in New Jersey

New Standards for an Old Disease:

TB Skin Test Practicum Houston, Texas Region 6/5 South September 23, 2014

Research in Tuberculosis: Translation into Practice

Latent Tuberculosis in Adults: From Testing TO Treatment

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

PEDIATRIC TUBERCULOSIS. Objectives. Children are not just small adults. Pediatric Tuberculosis 1

TB in the Patient with HIV

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

Didactic Series. Latent TB Infection in HIV Infection

PEDIATRIC TUBERCULOSIS

Diagnosis & Management of Latent TB Infection

Identifying TB co-infection : new approaches?

Contact Investigation and Prevention in the USA

Errors in Dx and Rx of TB

TB Intensive Houston, Texas October 15-17, 2013

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

The Most Widely Misunderstood Test of All

TB Intensive San Antonio, Texas November 11 14, 2014

Role of the Laboratory in TB Diagnosis and Management

Latent Tuberculosis Best Practices

Diagnosis and Management of Latent TB Infection Douglas Hornick, MD September 27, 2011

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

Ken Jost, BA, has the following disclosures to make:

TB Nurse Case Management Davenport, Iowa September 27 28, 2011

Tuberculosis: Where Are We Now?

LATENT TUBERCULOSIS. Robert F. Tyree, MD

The Diagnosis of Active TB. Deborah McMahan, MD TB Intensive September 28, 2017

Transcription:

What the Primary Physician Should Know about Tuberculosis Henry F. Chambers, M.D Professor of Medicine, UCSF Topics for Discussion Epidemiology Common disease presentations Diagnosis of active TB Screening for latent TB infection Global Impact of TB - 2010 World population 7,000,000,000 Number infected with TB: 2,300,000,000 New reported cases of active TB: 9,400,000 (140 per 100,000) US rate 3.6/100,000 in 2010 500,000 new MDR cases per year #1 cause of death worldwide from infectious disease (#2 AIDS, #3 malaria) 1

US Tuberculosis Case Rates 2010 (per 100,000) 11,181 cases for 350,000 Primary Care MDs MMWR Vol 60 (11):333,2011 US Tuberculosis Case Rates 2010 (per 100,000) MMWR Vol 60(11):333, 2011 Active Tuberculosis Pulmonary tuberculosis: 85% of all cases The infectious form of the disease Clinical suspicion based on Signs, symptoms, setting Chest x-ray 2

120 Sites of TB Infection Percent 100 80 60 40 20 0 All cases Expul Extrapulmonary Pulmonary Other Bone/jt Miliary GU Pleural Lymphatic Case Presentation 63 y/o inmate transferred from jail for r/o TB No fever, cough, weight loss 12 mm + PPD, HIV negative Prior work-up 2/2001: AFB smear/culture neg x3 4/2005: AFB smear/culture neg x3 8/2005: AFB smear/culture neg x3 3/2010: AFB smear/culture neg x1 9/2010: AFB smear/culture neg x4 CXR: LUL nodular infiltrate, slight volume loss, maybe slightly worse since prior film 3

What is your estimate of the likelihood of active TB in this case? 1. 75% or higher 2. 50-75% 3. 25-50% 4. 5-25% 5. < 5% Work-Up CXR: LUL nodular infiltrate, slight volume loss, maybe slightly worse since prior film? Sputum examination Routine: OF on culture and Gram-stain AFB x2 and BAL x1: no AFB GenProbe Amplified MTD test: negative What is your revised estimate of the likelihood of active TB in this case? 1. 75% or higher 2. 50-75% 3. 25-50% 4. 5-25% 5. < 5% 4

Diagnosis of TB 5

Performance of Diagnostic Tests for Pulmonary TB Sensitivity Specificity AFB smear 60% 99% NAA test 85% 99% Culture 90% 99% PPD (or QTF) 60% 10% Xpert MTB/RIF Test Performance Sensitivity Smear pos. TB 95-98% Smear neg. TB 60-72% Specificity 99% Rifampin R 98-99% 99-100% NEJM 361:1005, 2010; Am J Crit Care Med 184:132, 2011 Organism Burden in TB Cavitary TB Pulmonary infiltrate Lymphadenopathy 10 6-10 7 cfu/g 10 4-10 5 cfu/g 10 2-10 4 cfu/g 6

Detection Thresholds of Tests for TB Diagnosis Positive smear Positive NAA test Positive culture 10 4-10 5 cfu/ml 10 1-10 2 cfu/ml 10 1 cfu/ml Performance of NAAT for Diagnosis of Pulmonary TB Pre-test PPV NPV probability 90% 100% 43% 75% 98% 69% 50% 96% 87% 25% 91% 95% 5% 57% 99% Clinical Course Patient was discharged back to jail Treatment for tuberculosis withheld pending results of work-up 16 days after discharge, one sputum culture and the BAL specimen were reported positive for Mtb! 7

Extrapulmonary TB Forms of Extrapulmonary Tuberculosis Cervical lymphadenitis Tuberculous pleuritis Other rarer birds 8

Differential Dx of Cervical Adenitis Tuberculosis Non-tuberculous mycobacterial infection Kikuchi-Fujimoto s syndrome (histiocytic necrotizing lymphadenitis) Staph or strep infection Cat scratch Lymphoma, other tumor Other: syphilis, HIV, tularemia, listeria, plague Tuberculous Adenitis Clinically presentation not distinctive Constitutional symptoms not usually present Seen in children, young adults > adults PPD + in 75-80% Chest x-ray abnormality (15-20%) favors MTB Foreign-born patient more likely to have MTB 9

Work-up of Suspected TB Adenitis Tuberculin test Check HIV serology Chest x-ray to r/o pulmonary TB Respiratory isolation for patients with pulmonary symptoms, pulmonary TB Notify tuberculosis control Diagnosis of TB Adenitis Tissue is the issue to exclude other etiologies for sensitivity testing FNA Characteristic granulomas in 80% Culture + in 40-70% Smear + < 50% Biopsy: partial vs. total excision Treatment of TB Cervical Adenitis Responsive to medical therapy alone If excisional surgery performed, medical therapy still must be given Paradoxical worsening can occur; needle aspiration effective management Sinus track formation, non-healing wounds may benefit from surgery 10

Similar Scenario for TB Pleuritis Unilateral, benign, lymphocytic effusion Primary infection, newly + PPD Fluid usually smear and culture negative Pleural biopsy culture positive ~60%, with granulomas ~80% Treat as for adenitis or pulmonary TB Principles of Therapy Start 4 drugs (RIPE) for suspected active TB Never use a single drug for treating active TB: resistance can emerge (1 mutant in 10 4 to 10 6 ) Never add a single drug to a failing regimen Consult and expert and/or local health department Francis Curry National TB Center: http:// www.nationaltbcenter.edu/ Screening for Latent TB Infection (LTBI) 11

Case Presentation LV is a 58 y/o female from Ukraine referred for treatment of hypertension and diabetes She is otherwise well She gives a history of BCG vaccination as a teen What is the best course of action? 1. The patient should be screened for LTBI with a tuberculin test 2. The patient should not be screened for LTBI because she is not a candidate for INH prophylaxis due to her age 3. The patient should not be screened because with prior BCG vaccination the tuberculin test will be false positive 4. The patient should be screened for LTBI by chest x-ray LTBI: Goals of Screening Identify active cases Identify infected persons likely to benefit from treatment of latent TB infection (LTBI) Surveillance 12

Who Should Be Screened? Persons with increased risk of TB infection Persons with increased risk of progression Not the general population Increased Risk of Infection Recent contacts of an active TB case About 30% are infected Foreign-born persons from high TB prevalence areas Asia, Mexico, Middle East, Central and South America, Africa, Eastern Europe Medically underserved, low-income, racial and ethnic minorities Others: HCW, residents of congregate living settings Increased Risk of Progression Children < 5 years old Recent infection (contacts and converters HIV+ Prior TB Various medical conditions: Diabetes, hematologic/reticuloendotheial diseases, intestinal or gastric bypass, renal dialysis Malabsorption syndromes, malnutrition, silicosis, alcoholism, smokers Immunosuppression, anti-tnf agents > 15 mg prednisone QD for > 3 wks 13

Risk of Progression Risk Factor Increase in risk (+TST) AIDS/Advanced HIV 9.9 Anti-TNF agent 7.9 Old TB, untreated 5.2 Diabetes 3.1 Smoker 2.7 Underweight 1.6 Flowchart: Evaluation and Treatment of LTBI TB Risk? Yes No STOP Tuberculin Test + symptom review Negative Positive Treatment not indicated Normal Chest x-ray Abnormal Candidate for Rx of LTBI R/o active TB Diagnosis of LTBI TB Skin Test (TST) QuantiFERON Blood Test (QFT) 14

Reading the TST Measure reaction in 48 to 72 hours Measure induration, not erythema Record reaction in millimeters, not as negative or positive Positive reactions can be read for up to 7 days Negative reactions can be read accurately for only 72 hours TST Positivity 5 mm + PPD HIV, immunocompromised, contacts, abnl CXR 10 mm + PPD Those at increased risk of infection: IVDU, health care workers, foreign born, children < 4 yo, high-risk medical conditions 15 mm +PPD Persons not at risk (why did you do the test?) TST Conversion Signifies new infection > 10 mm increase within 2-year period Conversions may represent boosted reactions in some individuals 15

Tuberculin Skin Test Should NOT be performed on someone with a documented history of a positive test Should be applied, read, and interpreted by a trained health professional RULE OUT active TB before treating for LTBI Interferon Gamma Release Assays (IGRA) Indirect test for M. tuberculosis infection using whole blood Tests for generation of interferon gamma by cell-mediated immunity (not antibody) Highly specific: not affected by prior BCG vaccination Andersen, et al. Lancet 356:1099, 2000 16

FDA Approved Interferon Gamma Release Assays (IGRA) Quantiferon-TB Gold (Cellestis, Ltd) Uses ESAT-6 and CFP-10 as antigens Quantiferon-TB In-tube Uses ESAT-6, CFP-10 and TB7.7 (RD4) as antigens affixed to inside of tube T-Spot-TB (Oxford Immunotec) Uses ESAT-6 and CFP-10 IGRAS: Species Specificity of ESAT-6 and CFP-10 Mycobacterial species ESAT-6 CFP-10 M. tuberculosis + + M. africanum + + M. bovis + + BCG strains - - M. avium-intracellulare - - M. abscessus - - M. smegmatis - - M. kansasii + + M. marinum + + M. szulgai + + Quantiferon-Gold Advantages Requires a single patient visit to draw a blood sample Results within 24 hours No boosting Is not subject to reader bias that can occur with TST Is not affected by prior BCG 17

Performance of IGRA vs TST Performance characteristics TST IGRA Sensitivity 75-91% 80-95% Specificity 80-90% 95-100% Correlates with exposure Often no Yes Results change with Rx?? Usually yes When Should You Use QFT? QFT-G can be used in all circumstances in which the TST is currently used, including contact investigations evaluation of recent immigrants who have had BCG vaccination TB screening of health care workers others undergoing serial evaluation for M. tuberculosis Caution should be used when testing certain populations (i.e., children < 5 years old, immunocompromised) because of limited data in use of QFT Current Guidelines for Treatment of LTBI Decision to test is decision to treat No 35 year-old cut-off 9 months of INH preferred over 6 months Baseline lab monitoring not routinely indicated 18

Efficacy of INH Treatment of LTBI Duration of INH 5-yr risk reduction Compliance Reduction if compliant 3 mo 21% 87% 31% 6 mo 65% 78% 69% 9 mo 75% 68% 93% Bull World Health Organ 60:555, 1982 Rifapentine (Rfp) + INH for Rx of LTBI Regimen TB rate Compliance AE* (hepatitis) INH 300 mg qd x 9 mo 15/3745 69% 3.7% (0.4%) Rfp 900 mg + INH 900 mg 7/3986 82% qwk x 3 mo DOT NEJM 365:2155, 2011 4.9% (2.7%) * Treatment ending What is the best course of action? 1. The patient should be offered a tuberculin test to screen for LTBI 2. The patient should not be screened for LTBI because she is not a candidate for INH prophylaxis due to her age 3. The patient should not be screened with tuberculin test because with prior BCG vaccination the test will be false positive 4. The patient should be screened for LTBI by chest x-ray 19

Thanks! 20